Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001923541 | SCV002188434 | uncertain significance | Neuroblastoma, susceptibility to, 3 | 2022-06-27 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals affected with ALK-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.007%). This sequence change replaces aspartic acid, which is acidic and polar, with valine, which is neutral and non-polar, at codon 508 of the ALK protein (p.Asp508Val). |
Ambry Genetics | RCV004631825 | SCV005121018 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-04-05 | criteria provided, single submitter | clinical testing | The p.D508V variant (also known as c.1523A>T), located in coding exon 7 of the ALK gene, results from an A to T substitution at nucleotide position 1523. The aspartic acid at codon 508 is replaced by valine, an amino acid with highly dissimilar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |